Skip to content
Skip to content

The Ataxia Community Comes Together in Orlando April 9–11, 2026 for the Annual Ataxia Conference! LEARN MORE

Research Pipeline

Events

Support Groups

About NAF

Search

SCA3 FDA Patient-Led Listening Session Summary

READ FULL REPORT

EL-PFDD MEETING ON ATAXIA

GENERAL INFORMATION ABOUT SCA3

On September 22, 2023, the FDA hosted a listening session with advocates from the Spinocerebellar Ataxia Type 3 (SCA3) disease community. The National Ataxia Foundation and our partner organizations led efforts to invite SCA3 community members to share their experiences about living with the rare disease.

Session Objectives

  • To educate FDA staff on the complex issues, variety of physical manifestations, and body
    systems affected by this rare disorder.
  • To educate FDA staff on the serious impacts of SCA3 disease manifestations on patients and
    their quality of life.
  • To educate FDA staff on the scarcity of currently available treatments, tremendous unmet
    medical need, and preferences for future treatments and outcomes.

Topics Discussed

  • An overview of SCA3, including the cause of disease, disease progression, symptomology, and
    the impact on families and caregivers.
  • The symptoms and health effects most burdensome to people with SCA3.
  • The inadequacy of current treatments and unmet medical needs of patients with SCA3.
Print Friendly, PDF & Email
Translate »

Join the Ataxia community today!

Become a free member for exclusive content from NAF.

SIGN UP